Kenzo Shimazu

4.1k total citations
116 papers, 3.1k citations indexed

About

Kenzo Shimazu is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Kenzo Shimazu has authored 116 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 75 papers in Cancer Research, 58 papers in Oncology and 36 papers in Molecular Biology. Recurrent topics in Kenzo Shimazu's work include Breast Cancer Treatment Studies (50 papers), Cancer Genomics and Diagnostics (30 papers) and Breast Lesions and Carcinomas (25 papers). Kenzo Shimazu is often cited by papers focused on Breast Cancer Treatment Studies (50 papers), Cancer Genomics and Diagnostics (30 papers) and Breast Lesions and Carcinomas (25 papers). Kenzo Shimazu collaborates with scholars based in Japan, Russia and United States. Kenzo Shimazu's co-authors include Shinzaburo Noguchi, Yasuhiro Tamaki, Seung Jin Kim, Tomonori Tanei, Tetsuya Taguchi, Yasuto Naoi, Koji Morimoto, Naofumi Kagara, Atsushi Shimomura and Yoshio Tanji and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kenzo Shimazu

110 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenzo Shimazu Japan 28 1.6k 1.5k 977 629 597 116 3.1k
Atilla Ömeroğlu Canada 23 1.9k 1.2× 1.6k 1.1× 1.7k 1.7× 779 1.2× 619 1.0× 74 4.0k
In Ae Park South Korea 28 1.1k 0.7× 1.1k 0.7× 609 0.6× 561 0.9× 352 0.6× 72 2.6k
David N. Church United Kingdom 28 1.3k 0.8× 1.7k 1.2× 1.1k 1.1× 1.2k 2.0× 353 0.6× 75 4.4k
Alberto Bottini Italy 32 1.5k 1.0× 1.6k 1.1× 1.1k 1.1× 368 0.6× 201 0.3× 117 3.1k
Dorthe Grabau Sweden 28 1.6k 1.0× 1.5k 1.0× 1.3k 1.4× 380 0.6× 268 0.4× 57 3.0k
Gary A. Palmer United States 28 880 0.6× 1.3k 0.9× 936 1.0× 473 0.8× 650 1.1× 70 2.7k
Zhongwu Li China 30 683 0.4× 1.7k 1.1× 1.2k 1.2× 359 0.6× 665 1.1× 177 3.4k
Helena R. Chang United States 27 1.1k 0.7× 955 0.7× 683 0.7× 498 0.8× 270 0.5× 69 2.3k
G. Viale Italy 14 1.4k 0.9× 1.7k 1.2× 807 0.8× 511 0.8× 283 0.5× 47 3.0k
Rosalba Torrisi Italy 35 1.9k 1.2× 2.4k 1.6× 1.0k 1.0× 643 1.0× 273 0.5× 130 4.2k

Countries citing papers authored by Kenzo Shimazu

Since Specialization
Citations

This map shows the geographic impact of Kenzo Shimazu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenzo Shimazu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenzo Shimazu more than expected).

Fields of papers citing papers by Kenzo Shimazu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenzo Shimazu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenzo Shimazu. The network helps show where Kenzo Shimazu may publish in the future.

Co-authorship network of co-authors of Kenzo Shimazu

This figure shows the co-authorship network connecting the top 25 collaborators of Kenzo Shimazu. A scholar is included among the top collaborators of Kenzo Shimazu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenzo Shimazu. Kenzo Shimazu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Seno, Shigeto, Yasuto Naoi, Keiichiro Honma, et al.. (2025). IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses. Breast Cancer. 32(3). 566–581.
2.
3.
Shimoda, Masafumi, Kaori Abe, Tetsuhiro Yoshinami, et al.. (2025). Isolated splenic metastasis presenting at diagnosis of HER2-positive de novo metastatic breast cancer: a case report. Journal of Surgical Case Reports. 2025(9). rjaf751–rjaf751.
4.
Tanei, Tomonori, Shigeto Seno, Tetsuhiro Yoshinami, et al.. (2025). High HER2 Intratumoral Heterogeneity Is Resistant to Anti-HER2 Neoadjuvant Chemotherapy in Early Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers. 17(13). 2126–2126. 2 indexed citations
5.
Pradipta, Ambara R., Akihiro Ishiwata, H. YOSHIOKA, et al.. (2025). Cancer‐Selective Intracellular Polymerization via Acrolein‐Driven Cyclodimerization Cascade. Angewandte Chemie International Edition. 65(4). e18290–e18290.
6.
Shimoda, Masafumi, Yasufumi Sato, Kaori Abe, et al.. (2024). Prognostic value of serum tartrate‑resistant acid phosphatase‑5b for bone metastasis in patients with resectable breast cancer. Oncology Letters. 27(6). 250–250. 1 indexed citations
7.
Tanei, Tomonori, Shigeto Seno, Kaori Abe, et al.. (2024). High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer. Cancers. 16(5). 1062–1062. 5 indexed citations
8.
Abe, Kaori, Tadashi Watabe, Kazuko Kaneda‐Nakashima, et al.. (2024). Evaluation of Targeted Alpha Therapy Using [211At]FAPI1 in Triple-Negative Breast Cancer Xenograft Models. International Journal of Molecular Sciences. 25(21). 11567–11567. 2 indexed citations
9.
Hashimoto, Yoko, Naofumi Kagara, Kaori Abe, et al.. (2023). Detection of Ultra-Rare ESR1 Mutations in Primary Breast Cancer Using LNA-Clamp ddPCR. Cancers. 15(9). 2632–2632. 4 indexed citations
10.
Sato, Yasufumi, Masafumi Shimoda, Tomohiro Miyake, et al.. (2021). Enhanced humoral immunity in breast cancer patients with high serum concentration of anti‐HER2 autoantibody. Cancer Medicine. 10(4). 1418–1430. 9 indexed citations
11.
Naoi, Yasuto, Masafumi Shimoda, Tomonori Tanei, et al.. (2021). Impact of tumor cellularity on the HER2 amplification assay by OncoScan™ in breast cancer. Breast Cancer. 28(4). 977–982.
12.
Pradipta, Ambara R., Tomonori Tanei, Koji Morimoto, et al.. (2020). Emerging Technologies for Real‐Time Intraoperative Margin Assessment in Future Breast‐Conserving Surgery. Advanced Science. 7(9). 1901519–1901519. 75 indexed citations
13.
Kim, Seung Jin, Yasuto Naoi, Keiichiro Honma, et al.. (2020). Determining homologous recombination deficiency scores with whole exome sequencing and their association with responses to neoadjuvant chemotherapy in breast cancer. Translational Oncology. 14(2). 100986–100986. 12 indexed citations
14.
Pradipta, Ambara R., Tomonori Tanei, Koji Morimoto, et al.. (2019). Tetramethylrhodamine is an essential scaffold of azide probe in detecting cellular acrolein. Bioorganic & Medicinal Chemistry. 27(11). 2228–2234. 17 indexed citations
15.
Miyake, Tomohiro, Kenzo Shimazu, Tomonori Tanei, et al.. (2019). Hookwire-guided Sentinel Lymph Node Biopsy Using Contrast-enhanced Ultrasonography Followed by a One-step Nucleic Acid Amplification (OSNA) Assay for Breast Cancer. Anticancer Research. 39(11). 6183–6192. 7 indexed citations
16.
Naoi, Yasuto, Kenzo Shimazu, Masafumi Shimoda, et al.. (2019). Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. Breast Cancer Research and Treatment. 174(3). 627–637. 15 indexed citations
17.
Shimoda, Masafumi, Naofumi Kagara, Yasuto Naoi, et al.. (2016). Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. Breast Cancer Research and Treatment. 157(1). 55–63. 40 indexed citations
18.
Fujita, Noriko, Takahiro Nakayama, Noriaki Yamamoto, et al.. (2012). Methylated DNA and Total DNA in Serum Detected by One-Step Methylation-Specific PCR Is Predictive of Poor Prognosis for Breast Cancer Patients. Oncology. 83(5). 273–282. 49 indexed citations
19.
Tanei, Tomonori, Koji Morimoto, Kenzo Shimazu, et al.. (2009). Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers. Clinical Cancer Research. 15(12). 4234–4241. 475 indexed citations
20.
Akazawa, Kenji, Yasuhiro Tamaki, Tetsuya Taguchi, et al.. (2008). Potential of Reduction in Total Tumor Volume Measured with 3D-MRI as a Prognostic Factor for Locally-Advanced Breast Cancer Patients Treated with Primary Chemotherapy. The Breast Journal. 14(6). 523–531. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atilla Ömeroğlu Breakdown of academic impact, for papers by In Ae Park Breakdown of academic impact, for papers by David N. Church Breakdown of academic impact, for papers by Alberto Bottini Breakdown of academic impact, for papers by Dorthe Grabau Breakdown of academic impact, for papers by Gary A. Palmer Breakdown of academic impact, for papers by Zhongwu Li Breakdown of academic impact, for papers by Helena R. Chang Breakdown of academic impact, for papers by G. Viale Breakdown of academic impact, for papers by Rosalba Torrisi
Rankless by CCL
2026